{"contentid": 488002, "importid": NaN, "name": "AgomAb Therapeutics raises $74 million in Series B financing", "introduction": "Belgium\u00e2\u0080\u0099s AgomAb Therapeutics says it has closed a $74 million Series B financing round led by Redmile Group, which will further advance its lead compound AGMB-101.", "content": "<p>Belgium&rsquo;s AgomAb Therapeutics says it has closed a $74 million Series B financing round led by Redmile Group, which will further advance its lead compound AGMB-101.</p>\n<p>There was also participation from Cormorant Asset Management. All previous investors also participated in the round, including Advent France Biotechnology, Andera Partners, Boehringer Ingelheim Venture Fund, Omnes Capital, Pontifax, and V-Bio Ventures.</p>\n<p>The proceeds will be used to fund clinical proof-of-concept of the lead program AGMB-101, an HGF-mimetic agonistic antibody, which is currently progressing through investigational new drug (IND)-enabling studies. The capital will also support further growth of the company&rsquo;s pipeline of drug candidates designed to modulate regenerative pathways to induce functional organ recovery in acute and chronic diseases. In conjunction with the financing round, a Redmile representative will join the board of directors.</p>\n<p>&ldquo;The size and quality of this round reinforces the strong scientific foundation on which AgomAb was built and the support by our initial investors. It enables us to further accelerate our development progress and pipeline growth,&rdquo; said AgomAb chief executive Tim Knotnerus, noting that &ldquo;adding two top-tier US investors and expanding the leadership team is a very important strategic step for the company, supporting our vision of transforming regenerative medicine.&rdquo;</p>\n<h2><strong>Welcomes new executives</strong></h2>\n<p>In line with the financing and the company&rsquo;s commitment to becoming a leader in harnessing regenerative pathways, AgomAb welcomed key hires to its leadership team, including:</p>\n<p>Philippe Wiesel as chief medical officer, bringing more than 10 years of expertise in clinical development of treatments of fibrotic disorders. He previously held the position of CMO at Genkyotex;</p>\n<p>Paul van der Horst will join AgomAb as chief business Officer. most recently he served as the head of corporate development at Belgian biotech Galapagos (Euronext: GLPG), where he led major transactions, investments, licensing and M&amp;A activities for the company; and</p>\n<p>Tolga Hassan will support AgomAb as chief financial officer and contributes more than 25 years of strategic financial experience. He previously held the position of CFO at F-star Therapeutics.</p>\n<p>Full biographies can be found on the company&rsquo;s website through this&nbsp;<a href=\"https://agomab.com/building-agomab/#leadership\">link</a>.</p>", "date": "2021-03-10 16:15:00", "meta_title": "AgomAb Therapeutics raises $74 million Series B financing", "meta_keywords": "AgomAb Therapeutics, Series B financing,  AGMB-101, Appointments", "meta_description": "AgomAb Therapeutics raises $74 million Series B financing", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-10 16:14:43", "updated": "2021-03-10 16:24:08", "access": NaN, "url": "https://www.thepharmaletter.com/article/agomab-therapeutics-raises-74-million-series-b-financing", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "medicines_money_stock_large.jpg", "image2id": "medicines_money_stock_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": "Private Equity", "sector_tag": "Biotechnology", "therapy area_tag": "Regenerative Medicine", "topic_tag": "Boardroom, Business Financing, Management", "geography_tag": "Belgium", "company_tag": "AgomAb Therapeutics, REDMILE GROUP&#44;&nbsp; LLC", "drug_tag": "AGMB-101", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-10 16:15:00"}